VistaGen Therapeutics to Report 2021 Fiscal Year End Financial Results, Provide a Business Update and Host Conference Call an...
June 25 2021 - 8:00AM
VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical
company committed to developing a new generation of medicines with
the potential to go beyond the current standard of care for
anxiety, depression, and other central nervous system (“CNS”)
disorders, today announced that it will host a corporate update
conference call on Tuesday, June 29, 2021 at 2:00 pm
Pacific Time (5:00 pm Eastern Time) to discuss its financial
and operating results for its fiscal year ended March 31, 2021 and
provide a business update.
Event: VistaGen Therapeutics 2021 Fiscal
Year End Results and Business Update Conference
CallDate: Tuesday, June 29,
2021Time: 2:00 pm PT (5:00 pm
ET)US Dial-in (Toll
Free): 1-877-407-9716TOLL/International
Dial-in: 1-201-493-6779Conference
ID: 13720908
Shawn Singh, CEO of VistaGen, will host the call along with
other members of the Company’s management team. The call is open to
the public and will provide an update on recent developments,
milestones during the Company’s 2021 fiscal year, which ended March
31, 2021, and certain target milestones and goals for future
periods.
A live audio webcast of the conference call will also be
available via this link –
http://public.viavid.com/index.php?id=145419.
Participants should access this webcast site 10 minutes
before the start of the call. In addition, a telephone playback of
the call will be available after approximately 5:00 pm
PT on June 29, 2021. To listen to the replay, call toll
free 1-844-512-2921 within the United States or
1-412-317-6671 when calling internationally (toll). Please use the
replay PIN number 13720908.
About VistaGenVistaGen Therapeutics is a
biopharmaceutical company committed to developing and
commercializing innovative medicines with the potential to go
beyond the current standard of care for anxiety, depression, and
other CNS disorders. Each of VistaGen's three CNS drug candidates
has a differentiated profile and therapeutic potential in multiple
CNS markets. For more information, please
visit www.VistaGen.com and connect with VistaGen on Twitter,
LinkedIn, and Facebook.
VistaGen Company ContactsMark McPartland / Mark
FlatherVistaGen Therapeutics Phone: (650) 577-3606Email:
IR@vistagen.com
Vistagen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vistagen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Sep 2023 to Sep 2024